Почетна › Миелодиспластични синдроми › Северна Каролина
Клинички испитувања за Миелодиспластични синдроми во Северна Каролина
19 студии за Миелодиспластични синдроми бараат учесници на локации во Северна Каролина.
Градови во Северна Каролина
Официјален текст на студијата (англиски)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Duke University Medical Center, Durham
- East Carolina University, Greenville
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Wake Forest University Health Sciences, Winston-Salem
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- и уште 5
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Atrium Health Wake Forest Baptist, Winston-Salem
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health Care Institute, Winston-Salem
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- и уште 4
Се регрутираФаза 1/2
До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health-Cancer Institute, Winston-Salem
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 21.8.2026 · NCT06499285ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT06656494Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Duke Cancer Institute, Durham
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 10.8.2026 · NCT05308264Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Chapel Hill
- Research Site, Durham
Се регрутираФаза 1/2
Возраст 16 и постари · Сите полови · Ажурирано 20.7.2026 · NCT07155226Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- и уште 4
Се регрутираНабљудувачка студија
Возраст 65 и постари · Сите полови · Ажурирано 29.6.2026 · NCT01137825A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 30.4.2026 · NCT04256317The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
Се регрутираНабљудувачка студија
Возраст од 18 до 120 · Сите полови · Ажурирано 13.4.2026 · NCT01890486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- UNC Hospital, Chapel Hill
- Duke University, Durham
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 24.3.2026 · NCT04988555CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Duke Cancer Center, Durham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 16.1.2026 · NCT05143996SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Се регрутираНабљудувачка студија
Возраст од 18 до 120 · Сите полови · Ажурирано 27.10.2025 · NCT01137643Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.